Author name: DrugChatter

Walk into any pharmaceutical compliance team’s weekly meeting and you’ll find the same agenda items from the past decade: OPDP […]

How drug brands fought off-label prescribing to survive: real FDA cases, litigation wins, and what AI monitoring means for pharmacovigilance

There’s a repeating theme across DrugChatter: not “what are the side effects?” but “is this normal—or something I should worry

Pfizer paid $2.3 billion in 2009. GlaxoSmithKline paid $3 billion in 2012. AstraZeneca paid $520 million in 2010. Each of

Every so often the public conversation about medicines drifts into a familiar question: why is this one so expensive? But

There’s a quiet sorting mechanism in medicine that has little to do with pharmacology textbooks and everything to do with

If you spend enough time around athletes, weekend warriors, or anyone optimizing “fitness,” you start to notice a recurring theme:

Why migraine drugs became weight-loss forums, cholesterol pills turned into food-interaction experiments, and cancer therapies spawned Reddit-scale crowdsourced medicine. There’s

Inside the wonderfully unfiltered world of drug questions people actually ask online Spend enough time around pharmaceutical R&D and you

AI Pharmacovigilance: How Drug Companies Track Safety Signals Before Regulators Do The FDA receives roughly 2 million adverse event reports

Chatbots now answer drug questions that once required a detail rep, a pharmacist, or a Medical Information call center. The

AI Agents Now Influence Which Drugs Patients Ask For — Here’s the Pharma Playbook When a patient with newly diagnosed